Development of multi-route physiologically-based pharmacokinetic models for ethanol in the adult, pregnant, and neonatal rat

被引:16
作者
Martin, Sheppard A. [1 ]
McLanahan, Eva D. [2 ]
El-Masri, Hisham [3 ]
LeFew, William R. [3 ]
Bushnell, Philip J. [1 ]
Boyes, William K. [1 ]
Choi, Kyoungju [4 ]
Clewell, Harvey J., III [4 ]
Campbell, Jerry L., Jr. [4 ]
机构
[1] US EPA, NB, TAD, NHEERL,ORD, Res Triangle Pk, NC 27711 USA
[2] NCEA, ORD, Res Triangle Pk, NC USA
[3] ISTD, SBB, ORD, Res Triangle Pk, NC USA
[4] Hamner Inst Hlth Sci, Res Triangle Pk, NC USA
关键词
Ethanol; Pharmacokinetics; PBPK model; Multi-route; Life-stage; FETAL ALCOHOL SYNDROME; CEREBELLAR PURKINJE-CELLS; APOPTOTIC NEURODEGENERATION; GASTROINTESTINAL TRANSIT; DEHYDROGENASE ACTIVITY; SYNAPTIC PLASTICITY; COGNITIVE FUNCTION; OXIDIZING SYSTEM; DEVELOPING BRAIN; ANIMAL-MODEL;
D O I
10.3109/08958378.2012.712165
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Biofuel blends of 10% ethanol (EtOH) and gasoline are common in the USA, and higher EtOH concentrations are being considered (15-85%). Currently, no physiologically-based pharmacokinetic (PBPK) models are available to describe the kinetics of EtOH-based biofuels. PBPK models were developed to describe life-stage differences in the kinetics of EtOH alone in adult, pregnant, and neonatal rats for inhalation, oral, and intravenous routes of exposure, using data available in the open literature. Whereas ample data exist from gavage and intravenous routes of exposure, kinetic data from inhalation exposures are limited, particularly at concentrations producing blood and target tissue concentrations associated with developmental neurotoxicity. Compared to available data, the three models reported in this paper accurately predicted the kinetics of EtOH, including the absorption, peak concentration, and clearance across multiple datasets. In general, model predictions for adult and pregnant animals matched inhalation and intravenous datasets better than gavage data. The adult model was initially better able to predict the time-course of blood concentrations than was the neonatal model. However, after accounting for age-related changes in gastric uptake using the calibrated neonate model, simulations consistently reproduced the early kinetic behavior in blood. This work provides comprehensive multi-route life-stage models of EtOH pharmacokinetics and represents a first step in development of models for use with gasoline-EtOH blends, with additional potential applicability in investigation of the pharmacokinetics of EtOH abuse, addiction, and toxicity.
引用
收藏
页码:698 / 722
页数:25
相关论文
共 50 条
  • [11] A computer-aided framework for development, identification and management of physiologically-based pharmacokinetic models
    Heitzig, Martina
    Linninger, Andreas A.
    Sin, Gurkan
    Gani, Rafiqul
    COMPUTERS & CHEMICAL ENGINEERING, 2014, 71 : 677 - 698
  • [12] Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®
    Willmann, Stefan
    Thelen, Kirstin
    Lippert, Joerg
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (07) : 997 - 1007
  • [13] Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women
    Mendes, Mailys De Sousa
    Hirt, Deborah
    Urien, Saik
    Valade, Elodie
    Bouazza, Naim
    Foissac, Frantz
    Blanche, Stephane
    Treluyer, Jean-Marc
    Benaboud, Sihem
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (05) : 1031 - 1041
  • [14] The use of physiologically-based pharmacokinetic pharmacodynamic dosimetry models for chemical mixtures
    Yang, RSH
    ElMasri, HA
    Thomas, RS
    Constan, AA
    TOXICOLOGY LETTERS, 1995, 82-3 : 497 - 504
  • [15] Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data
    Christoph P. Hornik
    Huali Wu
    Andrea N. Edginton
    Kevin Watt
    Michael Cohen-Wolkowiez
    Daniel Gonzalez
    Clinical Pharmacokinetics, 2017, 56 : 1343 - 1353
  • [16] Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment
    Clark, LH
    Setzer, RW
    Barton, HA
    RISK ANALYSIS, 2004, 24 (06) : 1697 - 1717
  • [17] Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically-based pharmacokinetic modeling
    Clewell, RA
    Merrill, EA
    Yi, KY
    Mahle, DA
    Sterner, TR
    Fisher, JW
    Gearhart, JM
    TOXICOLOGICAL SCIENCES, 2003, 74 (02) : 416 - 436
  • [18] Estimation of ethanol infusion profile to produce specified BrAC time course using physiologically-based pharmacokinetic (PBPK) models
    Plawecki, MH
    DeCarlo, RA
    Ramchandani, VA
    O'Connor, S
    PROCEEDINGS OF THE 26TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-7, 2004, 26 : 778 - 781
  • [19] Development of a physiologically based pharmacokinetic model for bisphenol A in pregnant mice
    Kawamoto, Yuko
    Matsuyama, Wakoto
    Wada, Masahiro
    Hishikawa, Junko
    Chan, Melissa Pui Ling
    Nakayama, Aki
    Morisawa, Shinsuke
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 224 (02) : 182 - 191
  • [20] Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits
    Bussing, David
    K. Shah, Dhaval
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2020, 47 (06) : 597 - 612